Approval · Notice of Compliance 7692 · 2006
ACTONEL: Notice of Compliance 7692
Issued January 17, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7692
- Date
- January 17, 2006
- Company
- Procter & Gamble Pharmaceuticals Canada, IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: prevention of postmenopausal osteoporosis for the 35 mg once-a-week tablets
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | Not yet assigned | — |
Medicinal ingredients
- RISEDRONATE SODIUM 35 MG per TAB